Conference abstractPublished 22 May 2017

Pyrazolylamine derivatives reveal the conformational switching between type I and type II binding modes of anaplastic lymphoma kinase (ALK)

Authors: Su-Ying Wu

National Health Research Institutes, Taiwan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type-I binding mode, but only limited type-II ALK structural studies are available. Herein, we present the structure of ALK in complex with N1-(3-4-[([5-(tert-butyl)-3-isoxazolyl]aminocarbonyl) amino]-3-methylphenyl-1H-5-pyrazolyl)-4-[(4-methylpiperazino)methyl]benzamide (5a), a novel ALK inhibitor adopting a type- II binding mode. It revealed binding of 5a resulted in the conformational change and reposition of the activation loop, Ã?±C-helix, and juxtamembrane domain, which are all important domains for the autoinhibition mechanism and downstream signal pathway regulation of ALK. A structure-activity relationship study revealed that modifications to the structure of 5a led to significant differences in the ALK potency and altered the protein structure of ALK. To the best of our knowledge, this is the first structural biology study to directly observe how changes in the structure of a small molecule can regulate the switch between the type I and type II binding modes, and induce dramatic conformational changes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.

Try:

More from this journal

The newest in Journal of Proteomics & Bioinformatics.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Proteomics & Bioinformatics
  • SubjectBiochemistry & Biotechnology
  • BylineArticles whose byline prints “Su-Ying Wu”